Next generation antidepressants

Next generation antidepressants.

Over the past 50 y, there have been few mechanistically distinct drugs for the treatment of major depressive disorders, despite the fact that nearly two-thirds of patients do not achieve full remission of symptoms on currently available antidepressants (1). In addition, even when adequate remission is achieved, patients require 2–4 wk of treatment before any significant effects, increasing the ...

Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants

Recently, ketamine has been demonstrated to exert rapid-acting antidepressant effects in patients with depression, including those with treatment-resistant depression, and this discovery has been regarded as the most significant advance in drug development for the treatment of depression in over 50 years. To overcome unwanted side effects of ketamine, numerous approaches targeting glutamatergic...

Triple Reuptake Inhibitors: The Next Generation of Antidepressants

Depression has been associated with impaired neurotransmission of serotonergic, norepinephrinergic, and dopaminergic pathways, although most pharmacologic treatment strategies for depression enhance only serotonin and norepinephrine neurotransmission. Current drug development efforts are aimed at a new class of antidepressants which inhibit the reuptake of all three neurotransmitters in the hop...

Second-generation antidepressants.

new generation of antidepressants in pregnant women

although pregnancy was once thought to protect against psychiatric disorders, gravid and non gravid women have similar risks for major depression, at 10% to 15%. both depression and antidepressant treatment during pregnancy have been associated with risks. few medications have been proved unequivocally safe during pregnancy. although certain antidepressants have not been linked with an increase...